Ascendis Pharma A/S (ASND) Stock Rating Upgraded by Zacks Investment Research
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
A number of other analysts have also weighed in on the company. Leerink Swann restated a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, September 2nd. TheStreet upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th. Finally, Wedbush began coverage on Ascendis Pharma A/S in a report on Monday, September 26th. They set an “outperform” rating and a $34.00 target price for the company.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down 0.61% during mid-day trading on Monday, hitting $20.51. The company had a trading volume of 58,181 shares. Ascendis Pharma A/S has a 1-year low of $11.92 and a 1-year high of $21.79. The company has a 50-day moving average price of $0.00 and a 200-day moving average price of $0.00.
TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/28/ascendis-pharma-as-asnd-stock-rating-upgraded-by-zacks-investment-research.html.
Several hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. raised its stake in shares of Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock valued at $5,296,000 after buying an additional 1,700 shares in the last quarter. RA Capital Management LLC raised its stake in shares of Ascendis Pharma A/S by 7.9% in the third quarter. RA Capital Management LLC now owns 3,681,491 shares of the company’s stock valued at $73,998,000 after buying an additional 268,634 shares in the last quarter. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $14,985,000. Hedge funds and other institutional investors own 44.40% of the company’s stock.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.